KAPANOL (Mayne Pharma International Pty Ltd)
Product name
KAPANOL
Date registered
Evaluation commenced
Decision date
Approval time
218 working days (255)
Active ingredients
morphine sulfate pentahydrate
Registration type
EOI
Indication
KAPANOL (modified release capsules) is indicated for the symptomatic reduction of chronic breathlessness in the palliative care of patients with distressing breathlessness due to severe COPD, cardiac failure, malignancy or other cause. Kapanol should only be used after treatments for the underlying cause(s) of the breathlessness have been optimised and non-pharmacological treatments are not effective. Treatment with Kapanol in this setting should only be initiated by a specialist knowledgeable in its use.